Demonstrating its commitment to high standards, Pfizer Animal Health's research and development team made a significant breakthrough. They created unique cell lines that were able to express a newly discovered key receptor protein for the PRRS virus (PRRSv). This innovative thinking was pivotal in bringing Fostera PRRS to the pork industry.

"With more than half of weaning-age PRRSv-negative pigs becoming infected before going to market, this innovative vaccine option helps growing pigs defend themselves against a PRRSv challenge," says Steve Sornsen, DVM, MS, senior director, Veterinary Business Solutions at Pfizer Animal Health.

A challenge study demonstrated that Fostera PRRS, which is the first and only PRRSv vaccine to earn the label claim aid in prevention of PRRS respiratory disease, reduced lung lesions by 84 per cent and reduced overall respiratory clinical signs by 80 per cent. Additionally, results showed vaccination with Fostera PRRS improved average daily gain by 2.5 times compared to pigs in the placebo group.

"Fostera PRRS helps optimise performance by minimising the adverse affects of a subsequent PRRSv challenge, thereby allowing growing pigs to maximise their post-challenge weight gain," says Doug King, DVM, senior veterinarian at Pfizer Animal Health.

Fostera PRRS is the second product to launch under the Fostera brand name and is supported by in-field support, resources and diagnostics to help veterinarians and producers tackle this critical disease challenge.

Fostera PRRS is available from your veterinarian or animal health supplier. For more information, talk to your veterinarian, Pfizer Animal Health representative, visit PfizerPork.com/FosteraPRRS or call toll-free 855-424-7349.

Further Reading

-

Find out more information on PRRS by clicking here.